Ditchcarbon
  • Customers
  1. Organizations
  2. Kyowa Kirin
Public Profile
Pharmaceutical Preparation Manufacturing
JP
updated a month ago

Kyowa Kirin

Company website

Kyowa Kirin Co., Ltd., a prominent biopharmaceutical company, is headquartered in Tokyo, Japan (JP). Founded in 1949, the company has established a strong presence in the global healthcare industry, focusing on innovative drug development in areas such as oncology, nephrology, and immunology. Kyowa Kirin is renowned for its unique biologics and small molecule therapies, which leverage advanced technologies to address unmet medical needs. The company has achieved significant milestones, including the successful launch of several key products that have positioned it as a leader in the biopharmaceutical sector. With a commitment to research and development, Kyowa Kirin continues to expand its operational footprint across major regions, including North America, Europe, and Asia, solidifying its market position through strategic partnerships and a robust pipeline of therapeutic solutions.

DitchCarbon Score

How does Kyowa Kirin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

65

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Kyowa Kirin's score of 65 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.

81%

Let us know if this data was useful to you

Kyowa Kirin's reported carbon emissions

In 2023, Kyowa Kirin reported total carbon emissions of approximately 23,507,000 kg CO2e, comprising 16,780,000 kg CO2e from Scope 1 and 6,727,000 kg CO2e from Scope 2. The company has set ambitious targets to reduce its greenhouse gas emissions, aiming for a 55% reduction in Scope 1 and Scope 2 emissions by 2030 compared to 2019 levels. This target is part of a broader commitment to achieve net-zero emissions across its entire value chain by 2050, as outlined in the Kirin Group Environmental Vision 2050. Additionally, Kyowa Kirin has committed to a 42% reduction in Scope 1 and Scope 2 emissions by 2030 from a 2021 base year, with plans to measure and reduce Scope 3 emissions as well. The company’s emissions data is cascaded from its parent organization, Kirin Holdings Company, Limited, which influences its sustainability initiatives and targets. Kyowa Kirin's ongoing efforts reflect a strong commitment to addressing climate change and reducing its carbon footprint in alignment with industry standards and global climate goals.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20192020202120222023
Scope 1
17,244,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
34,687,000
00,000,000
00,000,000
00,000,000
0,000,000
Scope 3
-
-
00,000,000
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Kyowa Kirin's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Kyowa Kirin is in JP, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Kyowa Kirin is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Par Pharmaceutical

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Sumitomo Pharma America, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Bausch Health Cos

CA
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Somerset Pharmaceuticals, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Heron Therapeutics, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 12 days ago

Glaxosmithkline

GB
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250829.2
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy